Immunotherapies that turn
the complexity of a solid tumor
against itself


Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvax’s combination therapy uniquely captures the complete antigenic signature of a patient’s own tumor and converts it into a highly stimulatory ‘training program’ for the patient’s immune system. The comprehensive nature of this training is intended to result in both innate and adaptive immune stimulation to optimize long-term anti-tumor effects.

The company’s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer, with additional programs in other types of solid tumors.


At Imvax we strive to create an environment that will challenge, motivate, and reward our employees for meeting the changing demands of creating breakthrough therapeutics. Imvax has a highly collaborative structure that integrates co-workers with different skill sets. Imvax is located in the heart of historical Philadelphia in the Curtis Building where we have in-house state-of-the-art labs and office space overlooking Washington Square.